Endotype–phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease

[1]  Ø. Molberg,et al.  Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. , 2019, American journal of respiratory and critical care medicine.

[2]  D. Riches,et al.  Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases , 2019, European Respiratory Journal.

[3]  G. Raghu,et al.  Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. , 2019, The New England journal of medicine.

[4]  M. Kolb,et al.  The natural history of progressive fibrosing interstitial lung diseases , 2019, Respiratory Research.

[5]  Jong Sun Park,et al.  Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[6]  R. Elashoff,et al.  Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis , 2018, PloS one.

[7]  K. Brown,et al.  What's in a name? That which we call IPF, by any other name would act the same , 2018, European Respiratory Journal.

[8]  H. Collard,et al.  Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease , 2017, BMJ Open Respiratory Research.

[9]  T. Mustelin,et al.  Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis , 2017, JCI insight.

[10]  T. Ueland,et al.  High Level of Chemokine CCL18 Is Associated With Pulmonary Function Deterioration, Lung Fibrosis Progression, and Reduced Survival in Systemic Sclerosis. , 2016, Chest.

[11]  R. Elashoff,et al.  Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial , 2016, The Lancet. Respiratory medicine.

[12]  V. Thannickal,et al.  Alveolar epithelial disintegrity in pulmonary fibrosis. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[13]  Athol U. Wells,et al.  Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group , 2015, The Journal of Rheumatology.

[14]  Shandra L. Protzko,et al.  An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. , 2015, American journal of respiratory and critical care medicine.

[15]  D. Furst,et al.  Update of EULAR recommendations for the treatment of systemic sclerosis , 2015, Annals of the rheumatic diseases.

[16]  Alexander Pautsch,et al.  Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis , 2015, European Respiratory Journal.

[17]  H. Collard,et al.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[18]  R. Sussman,et al.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2014, The New England journal of medicine.

[19]  Joyce S Lee,et al.  Predicting survival across chronic interstitial lung disease: the ILD-GAP model. , 2014, Chest.

[20]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[21]  T. Maher.  Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. , 2012, Clinics in chest medicine.

[22]  A. Nicholson,et al.  Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[23]  D. Abraham,et al.  Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. , 2009, Arthritis and rheumatism.

[24]  L. Farkas,et al.  VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. , 2009, The Journal of clinical investigation.

[25]  C. Kielty,et al.  Vascular endothelial growth factor can signal through platelet-derived growth factor receptors , 2007, The Journal of cell biology.

[26]  A. Nicholson,et al.  Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. , 2007, American journal of respiratory and critical care medicine.

[27]  Demosthenes Bouros,et al.  Angiogenesis in Interstitial Lung Diseases: a pathogenetic hallmark or a bystander? , 2006, Respiratory research.

[28]  V. Duronio,et al.  Proliferation of Pulmonary Interstitial Fibroblasts Is Mediated by Transforming Growth Factor-β1-induced Release of Extracellular Fibroblast Growth Factor-2 and Phosphorylation of p38 MAPK and JNK* , 2005, Journal of Biological Chemistry.

[29]  A. Sasseville,et al.  Novel Fibrogenic Pathways Are Activated in Response to Endothelial Apoptosis: Implications in the Pathophysiology of Systemic Sclerosis1 , 2005, The Journal of Immunology.

[30]  M. Burdick,et al.  The Role of the Th2 CC Chemokine Ligand CCL17 in Pulmonary Fibrosis1 , 2004, The Journal of Immunology.

[31]  J. Bonner,et al.  Regulation of PDGF and its receptors in fibrotic diseases. , 2004, Cytokine & growth factor reviews.

[32]  K. Brown,et al.  Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. , 2004, American journal of respiratory and critical care medicine.

[33]  Takashi Suzuki,et al.  Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. , 2004, American journal of respiratory and critical care medicine.

[34]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[35]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[36]  Paul J. Friedman,et al.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors , 2002, American journal of respiratory and critical care medicine.

[37]  M. Burdick,et al.  Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. , 2001, The Journal of clinical investigation.

[38]  R. Elashoff,et al.  Augmented concentrations of CX 3 CL 1 are associated with interstitial lung disease in systemic sclerosis , 2018 .

[39]  A. Azuma,et al.  A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis , 2015 .